Humoral Immune Responses to EGFR-Derived Peptides Predict Progression-Free and Overall Survival of Non-Small Cell Lung Cancer Patients Receiving Gefitinib-Reference-Cited by-同舟云学术

Humoral Immune Responses to EGFR-Derived Peptides Predict Progression-Free and Overall Survival of Non-Small Cell Lung Cancer Patients Receiving Gefitinib

Published:2014-01-31 Issue:1 Volume:9 Page:e86667
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Azuma Koichi,Komatsu Nobukazu,Hattori Satoshi,Matsueda Satoko,Kawahara Akihiko,Sasada Tetsuro,Itoh Kyogo,Hoshino Tomoaki

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference38 articles.

1. Cancer burden in the year 2000: the global picture;DM Parkin;Eur J Cancer,2001

2. Untagling the ErbB signaling network;Y Yarden;Nat Rev Mol Cell Biol,2001

3. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;TJ Lynch;N Engl Med,2004

4. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy;JG Paez;Science,2004

5. Molecular mechanisms of epidermal growth factor receptor activation and response to gefitinib and other EGFR-targeting drugs;M Ono;Clin Cancer Res,2006

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunogenicity of Del19 EGFR mutations in Chinese patients affected by lung adenocarcinoma;BMC Immunology;2019-11-13

2. Peripheral White Blood Cell Subsets in Metastatic Colorectal Cancer Patients Treated with Cetuximab: The Potential Clinical Relevance;Frontiers in Immunology;2018-01-04

3. Mutant Epitopes in Cancer;Oncoimmunology;2017-12-14

4. Immune Responses to Epidermal Growth Factor Receptor (EGFR) and Their Application for Cancer Treatment;Frontiers in Pharmacology;2016-10-26